Conference Coverage: ASCO 2023 – Focus on Lung Cancer
Expert perspectives and strategic insights on the latest therapeutic developments and translational research in lung cancer treatment
June 16, 2023
Faculty Chair
Corey J. Langer, MD, FACP
University of Pennsylvania, Philadelphia, PA, USA
FACULTY MEMBERS
Enriqueta Felip, MD, PhD
Vall d’Hebron University Hospital, Barcelona, Spain
Marina Garassino, MD
National Cancer Institute of Milan, Italy
Roy Herbst, MD, PhD
Yale Cancer Center, New Haven, CT, USA
Benjamin Besse, MD, PhD
Institute Gustave Roussy, Villejuif, France
Solange Peters, MD, PhD
University of Lausanne, Switzerland
Lynette Sholl, MD
Dana-Farber Cancer Institute, Boston, MA, USA
Mark Socinski, MD
AdventHealth Cancer Institute, Orlando, FL, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Immunotherapy in Stage I–III NSCLC
- Immunotherapy in Stage IV NSCLC
- EGFR (common mutations): Resectable and Metastatic
- EGFR (exon 20 and other uncommon mutations)
- Oncogenic Fusions
- Oncogenic Mutations
- Other Targets in NSCLC/SCLC
